No. | SNP | Gout/hyperuricemia | Normal | OR (95% CI) | p-values |
---|---|---|---|---|---|
Relationship between gout and normal subjects ( n =13,088) | |||||
1 | rs3733589 (SLC2A9; chr4:9985700) | ||||
GG | 754 (42.38) | 4019 (35.62) | Â | Â | |
GA | 820 (46.09) | 5393 (47.80) | 0.81 (0.73-0.90) | 1.16e-04 | |
AA | 205 (11.52) | 1870 (16.58) | 0.58 (0.50-0.69) | 8.90e-11 | |
2 | rs3775948 (SLC2A9; Chr4:9993558) | ||||
GG | 719 (40.39) | 3721 (33.07) | Â | Â | |
GC | 835 (46.91) | 5386 (47.87) | 0.80 (0.72-0.89) | 6.40e-05 | |
CC | 226 (12.70) | 2144 (19.06) | 0.55 (0.47-0.64) | 3.74e-14 | |
3 | rs1014290 (SLC2A9; Chr4:10000237) | ||||
GG | 736 (41.30) | 3900 (34.53) | Â | Â | |
GA | 838 (47.03) | 5376 (47.60) | 0.83 (0.74-0.92) | 4.70e-04 | |
AA | 208 (11.67) | 2019 (17.88) | 0.55 (0.46-0.64) | 1.85e-13 | |
4 | rs17407555 (ZNF518B; chr4:10273370) | ||||
AA | 1155 (64.85) | 8146 (72.11) | Â | Â | |
AG | 563 (31.61) | 2896 (25.64) | 1.37 (1.23-1.53) | 1.38e-08 | |
GG | 63 (3.54) | 255 (2.26) | 1.74 (1.31-2.31) | 9.67e-05 | |
5 | rs2725231 (PKD2; chr4:88013803) | ||||
AA | 694 (39.01) | 5138 (45.52) | Â | Â | |
AG | 835 (46.94) | 5011 (44.39) | 1.23 (1.11-1.37) | 1.34e-04 | |
GG | 250 (14.05) | 1139 (10.09) | 1.63 (1.39-1.90) | 1.37e-09 | |
6 | rs3109823 (ABCG2; chr4:88143450) | ||||
CC | 942 (52.95) | 5154 (45.71) | Â | Â | |
CT | 711 (39.97) | 4954 (43.93) | 0.79 (0.71-0.87) | 6.06e-06 | |
TT | 126 (7.08) | 1168 (10.36) | 0.59 (0.48-0.72) | 1.09e-07 | |
7 | rs2622604 (ABCG2; chr4:88157772) | ||||
TT | 1017 (57.10 | 5388 (47.72) | Â | Â | |
TC | 654 (36.72) | 4875 (43.18) | 0.71 (0.64-0.79) | 2.06e-10 | |
CC | 110 (6.18) | 1027 (9.10) | 0.57 (0.46-0.70) | 6.43e-08 | |
8 | rs6532055 (ABCG2; chr4:88197235) | ||||
TT | 869 (48.93) | 4621 (41.00) | Â | Â | |
TC | 729 (41.05) | 5202 (46.15) | 0.75 (0.67-0.83) | 5.20e-08 | |
CC | 178 (10.02) | 1448 (12.85) | 0.65 (0.55-0.78) | 1.06e-06 | |
9 | rs72554040 (ABCG2; chr4:88231172) | ||||
GG | 544 (30.60) | 2644 (23.40) | Â | Â | |
GA | 824 (46.34) | 5581 (49.40) | 0.72 (0.64-0.81) | 3.03e-08 | |
AA | 410 (23.06) | 3072 (27.19) | 0.65 (0.56-0.74) | 7.15e-10 | |
10 | rs671 (ALDH2; chr12:111803962) | ||||
GG | 1031 (57.89) | 5656 (50.06) | Â | Â | |
GA | 624 (35.04) | 4695 (41.55) | 0.73 (0.66-0.81) | 5.89e-09 | |
AA | 126 (7.07) | 948 (8.39) | 0.73 (0.60-0.89) | 1.64e-03 | |
11 | rs78069066 (MAPKAPK5; chr12:111900120) | ||||
GG | 1020 (57.43) | 5601 (49.68) | Â | Â | |
GA | 630 (35.47) | 4706 (41.74) | 0.74 (0.66-0.82) | 1.41e-08 | |
AA | 126 (7.09) | 967 (8.58) | 0.72 (0.59-0.87) | 8.40e-04 | |
12 | rs77768175 (HECTD4; chr12:112298314) | ||||
0AA | 1029 (57.87) | 5641 (50.05) | Â | Â | |
1AG | 625 (35.15) | 4688 (41.60) | 0.73 (0.66-0.81) | 7.66e-09 | |
2GG | 124 (6.97) | 941 (8.35) | 0.72 (0.59-0.88) | 1.28e-03 | |
Relationship between hyperuricemia and normal subjects ( n =16,395) | |||||
1 | rs10805346 (SLC2A9; chr4:9918723) | ||||
TT | 2302 (45.28) | 5677 (50.28) | Â | Â | |
TC | 2251 (44.28) | 4626 (40.97) | 1.20 (1.12-1.29) | 3.11e-07 | |
CC | 531 (10.44) | 988 (8.75) | 1.33 (1.18-1.49) | 1.86e-06 | |
2 | rs3733589 (SLC2A9; chr4:9985700) | ||||
GG | 2005 (39.45) | 4019 (35.62) | Â | Â | |
GA | 2441 (48.02) | 5393 (47.80) | 0.91 (0.84-0.97) | 7.93e-03 | |
AA | 637 (12.53) | 1870 (16.58) | 0.68 (0.62-0.76) | 7.77e-13 | |
3 | rs3775948 (SLC2A9, Chr4:9993558) | ||||
GG | 1886 (37.18) | 3721 (33.07) | Â | Â | |
GC | 2490 (49.08) | 5386 (47.87) | 0.91 (0.85-0.98) | 1.34e-02 | |
CC | 697 (13.74) | 2144 (19.06) | 0.64 (0.58-0.71) | 9.57e-18 | |
4 | rs1014290 (SLC2A9; chr4:10000237) | ||||
GG | 1957 (38.49) | 3900 (34.53) | Â | Â | |
GA | 2464 (48.46) | 5376 (47.60) | 0.91 (0.85-0.98) | 1.40e-02 | |
AA | 664 (13.06) | 2019 (17.88) | 0.64 (0.57-0.71) | 1.56e-17 |